Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice

被引：30
|
作者：
Lees, CJ
Apostolopoulos, V
Acres, B
Ramshaw, I
Ramsay, A
Ong, CS
McKenzie, IFC
机构：
[1] Austin Res Inst, Melbourne, Vic 3084, Australia
[2] Victoria Univ Technol, Ctr Bioproc & Food Technol, Werribee, Vic 3030, Australia
[3] Transgene SA, Dept Immunobiol, F-67082 Strasbourg, France
[4] Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol, Canberra, ACT 2601, Australia
来源：
VACCINE | 2000年 / 19卷 / 2-3期
关键词：
cytokines; transgenic; MUC1;
D O I：
10.1016/S0264-410X(00)00065-7
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic;mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：158 / 162
页数：5
相关论文
共 50 条
  • [41] RUNNING A MUC1
    McCarthy, Nicola
    NATURE REVIEWS CANCER, 2012, 12 (05) : 317 - 317
  • [42] Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
    Karanikas, V
    Hwang, LA
    Pearson, J
    Ong, CS
    Apostolopoulos, V
    Vaughan, H
    Xing, PX
    Jamieson, G
    Pietersz, G
    Tait, B
    Broadbent, R
    Thynne, G
    McKenzie, IFC
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11): : 2783 - 2792
  • [43] Expression of MUC1 and MUC2 in mammary carcinomas: Prognostic significance of a sialylated MUC1 epitope
    不详
    PATHOLOGY RESEARCH AND PRACTICE, 2005, 201 (03) : 170 - 170
  • [44] Detection of circulating mammary mucin (MUC1) and MUC1 immune complexes (MUC1-CIC) in healthy women
    Croce, MV
    Isla-Larrain, MT
    Price, MR
    Segal-Eiras, A
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02): : 112 - 120
  • [45] MUC1 and MUC2 in pancreatic neoplasia
    Levi, E
    Klimstra, DS
    Adsay, NV
    Andea, A
    Basturk, O
    JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (05) : 456 - 462
  • [46] Inhibiting MUC1 a/b chain interaction mediates cytotoxicity of cells expressing MUC1: The MUC1 dyad oncoprotein as a functional target
    Karmely, M.
    Rubinstein, D. B.
    Pichinuk, E.
    Ziv, R.
    Benhar, I.
    Feng, N.
    Wreschner, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue
    Schut, IC
    Waterfall, PM
    Ross, M
    O'Sullivan, C
    Miller, WR
    Habib, FK
    Bayne, CW
    BJU INTERNATIONAL, 2003, 91 (03) : 278 - 283
  • [48] Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice
    Wang, Helen H.
    Afdhal, Nezam H.
    Gendler, Sandra J.
    Wang, David Q. -H.
    GASTROENTEROLOGY, 2006, 131 (01) : 210 - 222
  • [49] The decision between tolerance and immunity to MUC1 is based on the differences in MUC1 glycosylation
    Ryan, Sean O.
    Wong, Man Yan
    Turner, Michael S.
    Vlad, Anda M.
    Finn, Olivera J.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S265 - S266
  • [50] MUC1 in Cancer Immunotherapy — New Hope or Phantom Menace?
    M. S. Syrkina
    M. A. Rubtsov
    Biochemistry (Moscow), 2019, 84 : 773 - 781
12345